• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeting IGF-1R: throwing out the baby with the bathwater?

作者信息

Basu B, Olmos D, de Bono J S

出版信息

Br J Cancer. 2011 Jan 4;104(1):1-3. doi: 10.1038/sj.bjc.6606023.

DOI:10.1038/sj.bjc.6606023
PMID:21206496
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3039814/
Abstract
摘要

相似文献

1
Targeting IGF-1R: throwing out the baby with the bathwater?靶向胰岛素样生长因子-1受体（IGF-1R）：是否因噎废食？
Br J Cancer. 2011 Jan 4;104(1):1-3. doi: 10.1038/sj.bjc.6606023.
2
Insulin-like growth factor receptor inhibitors: baby or the bathwater?胰岛素样生长因子受体抑制剂：是弃之可惜，还是全盘否定？
J Natl Cancer Inst. 2012 Jul 3;104(13):975-81. doi: 10.1093/jnci/djs258.
3
The potential role of insulin-like growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer.胰岛素样生长因子受体抑制剂在治疗晚期非小细胞肺癌中的潜在作用。
Expert Opin Investig Drugs. 2010 May;19(5):631-9. doi: 10.1517/13543781003767434.
4
Combination of anti-IGF-1R antibody A12 and ionizing radiation in upper respiratory tract cancers.抗 IGF-1R 抗体 A12 与电离辐射联合治疗上呼吸道癌。
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1179-87. doi: 10.1016/j.ijrobp.2010.10.003. Epub 2010 Dec 2.
5
Metformin Enhances the Therapy Effects of Anti-IGF-1R mAb Figitumumab to NSCLC.二甲双胍增强抗IGF-1R单克隆抗体菲妥珠单抗对非小细胞肺癌的治疗效果。
Sci Rep. 2016 Aug 4;6:31072. doi: 10.1038/srep31072.
6
Inhibition of insulin-like growth factor 1 receptor by CP-751,871 radiosensitizes non-small cell lung cancer cells.CP-751,871对胰岛素样生长因子1受体的抑制作用使非小细胞肺癌细胞对放疗更加敏感。
Clin Cancer Res. 2009 Aug 15;15(16):5117-25. doi: 10.1158/1078-0432.CCR-09-0478. Epub 2009 Aug 11.
7
[Targeting insulin-like growth factors in the treatment of cancer].[靶向胰岛素样生长因子治疗癌症]
Rev Mal Respir. 2010 Oct;27(8):959-63. doi: 10.1016/j.rmr.2010.07.005. Epub 2010 Sep 17.
8
Activation of insulin-like growth factor receptor signaling mediates resistance to histone deacetylase inhibitors.胰岛素样生长因子受体信号的激活介导了对组蛋白去乙酰化酶抑制剂的耐药性。
Cancer Lett. 2015 Jun 1;361(2):197-206. doi: 10.1016/j.canlet.2015.02.038. Epub 2015 Feb 23.
9
Development of the monoclonal antibody figitumumab, targeting the insulin-like growth factor-1 receptor, for the treatment of patients with non-small-cell lung cancer.开发针对胰岛素样生长因子-1 受体的单克隆抗体 figitumumab，用于治疗非小细胞肺癌患者。
Clin Lung Cancer. 2009 Jul;10(4):273-80. doi: 10.3816/CLC.2009.n.038.
10
Effects of insulin-like growth factor 1 receptor and its inhibitor AG1024 on the progress of lung cancer.胰岛素样生长因子1受体及其抑制剂AG1024对肺癌进展的影响。
J Huazhong Univ Sci Technolog Med Sci. 2015 Dec;35(6):834-841. doi: 10.1007/s11596-015-1515-1. Epub 2015 Dec 16.

引用本文的文献

1
Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours.两项关于 xentuzumab（一种人源化胰岛素样生长因子（IGF）中和抗体）在晚期实体瘤患者中的首次人体研究。
Br J Cancer. 2020 Apr;122(9):1324-1332. doi: 10.1038/s41416-020-0774-1. Epub 2020 Mar 12.
2
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.葡萄糖代谢靶向治疗和睡茄素A对表皮生长因子受体酪氨酸激酶抑制剂诱导的药物耐受持久性细胞有效。
Cancer Sci. 2017 Jul;108(7):1368-1377. doi: 10.1111/cas.13266. Epub 2017 Jun 19.
3
Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.胰岛素样生长因子-胰岛素受体底物（IGF-IRS）途径中的单核苷酸多态性与参加FIRE-3试验的转移性结直肠癌（mCRC）患者的预后相关。
Int J Cancer. 2017 Jul 15;141(2):383-392. doi: 10.1002/ijc.30715. Epub 2017 May 10.
4
Combine and conquer: challenges for targeted therapy combinations in early phase trials.联合并攻克：早期试验中靶向治疗联合方案面临的挑战
Nat Rev Clin Oncol. 2017 Jan;14(1):57-66. doi: 10.1038/nrclinonc.2016.96. Epub 2016 Jul 5.
5
Understanding the Key to Targeting the IGF Axis in Cancer: A Biomarker Assessment.了解癌症中靶向IGF轴的关键：生物标志物评估
Front Oncol. 2015 Jul 8;5:142. doi: 10.3389/fonc.2015.00142. eCollection 2015.
6
Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer.胰岛素样生长因子 1 受体基因表达作为非小细胞肺癌预后因素的相关性。
J Cancer Res Clin Oncol. 2015 Jan;141(1):43-53. doi: 10.1007/s00432-014-1787-z. Epub 2014 Aug 1.
7
Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly.肉瘤个体化治疗的前景与陷阱：从儿童、青少年和青年到老年人
Curr Oncol Rep. 2014 Sep;16(9):401. doi: 10.1007/s11912-014-0401-5.
8
Theranostic applications of antibodies in oncology.抗体在肿瘤学中的诊疗应用。
Mol Oncol. 2014 Jun;8(4):799-812. doi: 10.1016/j.molonc.2014.03.010. Epub 2014 Mar 21.
9
Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor.双重抑制胰岛素受体和胰岛素样生长因子-1 受体靶向非小细胞肺癌细胞。
PLoS One. 2013 Jun 24;8(6):e66963. doi: 10.1371/journal.pone.0066963. Print 2013.
10
Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.针对 1 型胰岛素样生长因子受体 (IGF-1R) 的人源化单克隆抗体 AVE1642 的 I 期研究，与抗癌疗法联合用于晚期实体瘤患者。
Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26.

本文引用的文献

1
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.循环游离 IGF-1 的预处理水平可识别出从 figitumumab 治疗中获益的 NSCLC 患者。
Br J Cancer. 2011 Jan 4;104(1):68-74. doi: 10.1038/sj.bjc.6605972. Epub 2010 Nov 23.
2
Targeting insulin-like growth factor signaling: rational combination strategies.靶向胰岛素样生长因子信号传导：合理的联合策略。
Mol Cancer Ther. 2010 Sep;9(9):2447-9. doi: 10.1158/1535-7163.MCT-10-0719. Epub 2010 Aug 31.
3
Molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor I receptor inhibition.非小细胞肺癌的分子分析确定了对胰岛素样生长因子 I 受体抑制具有不同敏感性的亚组。
Clin Cancer Res. 2010 Sep 15;16(18):4654-65. doi: 10.1158/1078-0432.CCR-10-0089. Epub 2010 Jul 29.
4
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.胰岛素样生长因子-I 受体抑制剂 figitumumab（CP-751,871）联合多西他赛治疗晚期实体瘤患者的Ib 期剂量递增、开放标签研究结果。
Br J Cancer. 2010 Jul 27;103(3):332-9. doi: 10.1038/sj.bjc.6605767. Epub 2010 Jul 13.
5
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.胰岛素受体在功能上增强多阶段肿瘤进展，并赋予对 IGF-1R 靶向治疗的内在抗性。
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10791-8. doi: 10.1073/pnas.0914076107. Epub 2010 May 10.
6
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.在肉瘤和尤文肉瘤患者中抗 IGF-1R 抗体 figitumumab（CP-751,871）的安全性、药代动力学和初步活性：一项 1 期扩展队列研究。
Lancet Oncol. 2010 Feb;11(2):129-35. doi: 10.1016/S1470-2045(09)70354-7. Epub 2009 Dec 23.
7
Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor figitumumab (CP-751,871) in combination with paclitaxel and carboplatin.胰岛素样生长因子 1 型受体抑制剂 figitumumab（CP-751,871）联合紫杉醇和卡铂的安全性、药代动力学和药效学。
J Thorac Oncol. 2009 Nov;4(11):1397-403. doi: 10.1097/JTO.0b013e3181ba2f1d.
8
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.吉非替尼或卡铂-紫杉醇用于治疗肺腺癌。
N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.
9
Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer.抗胰岛素样生长因子1型受体抗体CP-751,871联合紫杉醇和卡铂用于既往未治疗的局部晚期或转移性非小细胞肺癌的II期研究。
J Clin Oncol. 2009 May 20;27(15):2516-22. doi: 10.1200/JCO.2008.19.9331. Epub 2009 Apr 20.
10
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma.抗胰岛素样生长因子1型受体单克隆抗体CP-751,871在多发性骨髓瘤患者中的I期药代动力学和药效学研究。
J Clin Oncol. 2008 Jul 1;26(19):3196-203. doi: 10.1200/JCO.2007.15.9319. Epub 2008 May 12.